EICHORCondition: Parkinson Disease · Sponsor: Neuraly, Inc.
This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated form of exenatide, may be beneficial in PD and is being developed as a potential treatment for neurodegenerative disorders.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Patients who are diagnosed with Parkinson's disease according to UK Parkinson's Disease Society Brain Bank Clinical Diagnostic criteria or Movement Disorder Society Research Criteria * Patients with Parkinson's disease according to protocol specified scale assessments * DaTscan consistent with diagnosis of Parkinson's Disease * Men or women 30 to 80 years of age Exclusion Criteria: * Diagnosis of secondary or atypical parkinsonism * Prior use of dopaminergic treatment or MAO-B inhibitors for more than 28 days * Medical or recreational use of marijuana or THC-containing compounds within 3 months of screening visit * Pregnant or planning to become pregnant * Metabolic, surgical, psychiatric or laboratory abnormality that would interfere with study compliance or safety in the judgment of the investigator
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| St. Joseph's Hospital and Medical Center - Barrow Neurological Institute | Phoenix, Arizona, United States | — |
| Movement Disorders Center | Scottsdale, Arizona, United States | — |
| Mayo Clinic Arizona, Mayo Clinic Scottsdale | Scottsdale, Arizona, United States | — |
| Banner Sun Health Research Institute | Sun City, Arizona, United States | — |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | — |
| University of California, Irvine | Irvine, California, United States | — |
| Keck School of Medicine of USC/University of Southern California | Los Angeles, California, United States | — |
| University of California, Los Angeles, Center for Neurotherapeutics | Los Angeles, California, United States | — |
| SC3 Research | Pasadena, California, United States | — |
| University of California Davis Health | Sacramento, California, United States | — |
| University of California, San Francisco | San Francisco, California, United States | — |
+ 49 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04154072